Amy McBride Wendell
At a glance: Amy McBride Wendell is Director at Axogen (AXGN). Their latest SEC Form 4, filed Aug 12, 2026, reported a sale of $647K. On file: 1 purchase line ($100K) and 5 sale lines ($2.0M).
Disclosed holdings: about $6.0M of AXGN stock: 107,976 shares reported on their latest Form 4 (filed Aug 12, 2026), valued at the Nov 20, 2026 close of $55.73. This counts only AXGN shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Axogen, Inc. (AXGN); Director at Solventum Corp (SOLV)
Purchase track record
Not enough history. Based on 1 purchase with a full 90 days of price history.
Amy McBride Wendell's InsiderPrint
7 trades from SEC Form 4 filings, 2023 to 2026, drawn as one fingerprint.
Reading this print: Mostly sells, trading about 2 times a year, typically $147K a trade.
- Bump outward: a purchase (2)
- Dent inward: a sale (5)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Jason HarinsteinDirector · LUCK · 94% match
- Jim H. SnabeDirector · AI · 93% matchTheir buys since 2021: 1 of 3 beat the S&P 500
- Al J. HirshbergDirector · NE · 92% match
- Adam R. CraigChair · XFOR · 92% match
- Anthony S. GibneySee Remarks · AURA · 92% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Every purchase since 2023
From the SEC's insider data sets: each open-market buy by Amy McBride Wendell, matched to how the stock did over the next 90 days against the S&P 500.
1 of 1 buy beat the S&P 500 (100%), median +29.8% vs. the index. Small sample: treat with care. All insider buys: 46%.
| Stock | Filed | 90 days vs. S&P 500 |
|---|---|---|
| AXGN | Sep 8, 2023 | +29.8% |
Buys made close together in one stock count once. Price-only returns; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 12SEC | AXGNAxogen, Inc. | Sell Plan | 13,353107,976 held (−11%) | $48.42 | $647K | +15.1% |
| May 12SEC | AXGNAxogen, Inc. | Sell | 1,64793,826 held (−2%) | $42.60 | $70K | +30.8% |
| Mar 11SEC | SOLVSolventum CorpFirst buy | Buy | 1,4755,039 held (+41%) | $68.03 | $100K | +25.7% |
| Dec 17SEC | AXGNAxogen, Inc. | Sell | 5,000132,510 held (−4%) | $29.31 | $147K | +90.1% |
| Dec 17SEC | AXGNAxogen, Inc. | Sell | 20,436112,074 held (−15%) | $29.31 | $599K | +90.1% |
| Dec 17SEC | AXGNAxogen, Inc. | Sell | 18,24893,826 held (−16%) | $29.31 | $535K | +90.1% |
- Sell
Director Amy Mcbride Wendell sold $647K of AXGN at $48.42 — pre-scheduled 10b5-1 plan sale.
- Buy
Director Amy Mcbride Wendell bought $100K of SOLV at $68.03 — first open-market purchase in our records; raises the stake by 41%.
Follow Amy McBride Wendell
Get one email when Amy McBride Wendell files a new purchase or sale. Free.
At most one email a day about Amy McBride Wendell, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.